Contrarius funds report 0.6% Intellia (NTLA) holding in 13G/A

Rhea-AI Filing Summary

Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited report beneficial ownership of 714,480 shares of Intellia Therapeutics, Inc.0.6% of the class as of the event date.

The firms have shared voting and dispositive power over all 714,480 shares and no sole power. They state that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Intellia. The filing is made jointly because the two entities may be deemed a group under section 13(d)(3).

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

INTELLIA THERAPEUTICS, INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

45826J105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45826J105

1

Names of Reporting Persons

Contrarius Investment Management Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 714,480.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 714,480.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

714,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: Equivalent to IA.

SCHEDULE 13G

CUSIP No. 45826J105

1

Names of Reporting Persons

Contrarius Investment Management (Bermuda) Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

BERMUDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 714,480.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 714,480.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

714,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: Equivalent to IA.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: INTELLIA THERAPEUTICS, INC
(b)	Address of issuer's principal executive offices: 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139
Item 2.
(a)	Name of person filing: Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited
(b)	Address or principal business office or, if none, residence: Contrarius Investment Management Limited - 2 Bond Street, St Helier, Jersey, JE2 3NP, Channel Islands. Contrarius Investment Management (Bermuda) Limited - Waterloo House 100 Pitts Bay Road, Pembroke, HM 08 Bermuda
(c)	Citizenship: Contrarius Investment Management Limited is a company organized under the laws of Jersey, Channel Islands. Contrarius Investment Management (Bermuda) Limited is a company organized under the laws of Bermuda.
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 45826J105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Equivalent to IA.
Item 4.	Ownership
(a)	Amount beneficially owned: 714,480
(b)	Percent of class: 0.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 714,480
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 714,480
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited are together making this filing because they may be deemed to constitute a "group" for the purposes of section 13(d)(3) of the Act.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Contrarius Investment Management Ltd

Signature:	/s/ Thomas Daniel Perkins
Name/Title:	Thomas Daniel Perkins / Director
Date:	02/11/2026

Contrarius Investment Management (Bermuda) Ltd

Signature:	/s/ Matt De Kock
Name/Title:	Matt De Kock / Director
Date:	02/11/2026

FAQ

What stake in Intellia Therapeutics (NTLA) do Contrarius entities report?

Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited report beneficial ownership of 714,480 shares of Intellia Therapeutics common stock, representing 0.6% of the outstanding class as of the event date disclosed in the Schedule 13G/A.

Do Contrarius entities have control intent over Intellia Therapeutics (NTLA)?

No. The filing certifies the shares were acquired and are held in the ordinary course of business and not for changing or influencing control of Intellia. They also confirm the holdings are not part of any control-related transaction.

How is voting and dispositive power over Intellia (NTLA) shares structured?

The Contrarius entities report 0 shares with sole voting or dispositive power and 714,480 shares with shared voting and shared dispositive power. This means decisions over these shares are made jointly rather than by either entity alone.

Why are two Contrarius entities jointly filing for Intellia (NTLA)?

Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited file jointly because they may be deemed a group under section 13(d)(3) of the Exchange Act. The filing explains they are together making the ownership disclosure.

Is the Contrarius ownership in Intellia (NTLA) above or below 5%?

The reported Intellia stake is 0.6% of the class, and the filing notes ownership of 5 percent or less of the common stock. This places the Contrarius position well below the 5% large-shareholder threshold.

What type of reporting persons are the Contrarius entities in the Intellia (NTLA) filing?

Each Contrarius entity is classified as an investment adviser equivalent (IA) for reporting purposes. They also certify that their foreign regulatory regimes are substantially comparable to those of functionally equivalent U.S. institutions.